Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or
MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic
nasopharyngeal carcinoma (NPC).